ArticleMolecular cancer2022

Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.

Isabel Heidegger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.